Epilepsy is a neurological disorder that affects approximately 50 million people worldwide and is characterized by recurrent seizures. Traditionally, pharmaceuticals have been the main treatment option for epilepsy. However, new technologies such as neuromodulation devices are changing the landscape of epilepsy management.
Epilepsy is a seizure disorder caused by abnormal electrical activity in the brain, leading to a range of symptoms from loss of awareness to full-body seizures. The disorder poses a significant challenge for healthcare professionals and patients due to its various causes and severity levels, with some cases having known genetic factors while others remain unknown.
Neuromodulation devices like deep brain stimulators (DBS) and vagus nerve stimulators (VNS) offer innovative ways to manage seizures. DBS consists of an implantable pulse generator that sends electrical stimulation through electrodes implanted in the brain, while VNS uses electrical stimulation on the vagus nerve. These devices modulate neural activity to potentially reduce the frequency and severity of seizures.
The neuromodulation device market was impacted by the COVID-19 pandemic as non-life-threatening procedures were deprioritized. However, GlobalData predicts steady growth for this market in the coming years. Forecasts show positive growth for neuromodulation devices, with DBS and VNS segments expected to see compound annual growth rates of 6.53% and 5.92%, respectively, between 2023 and 2033.
In conclusion, neuromodulation devices are becoming a pioneering technology in the treatment of epilepsy, offering new possibilities for managing seizures. The future looks promising for the growth of these devices in the market.